# Developing World Study for RotaTeq™ (V260-015)(COMPLETED)

> **NCT00362648** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 7504 (actual)

## Conditions studied

- Vomiting
- Diarrhea
- Fever

## Interventions

- **BIOLOGICAL:** RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent
- **BIOLOGICAL:** Comparator: Placebo

## Key facts

- **NCT ID:** NCT00362648
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 7504 (ACTUAL)
- **Last updated:** 2017-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00362648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00362648, "Developing World Study for RotaTeq™ (V260-015)(COMPLETED)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00362648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*